El Uso de Alb-PRF como un Sistema de “Drug Delivery” para el Tratamiento de Lesiones Malignas
DOI:
https://doi.org/10.32635/2176-9745.RBC.2023v69n2.3762Palabras clave:
fibrina rica en plaquetas, sistemas de liberación de medicamentos, plasma rico en plaquetas, nanopartículas, neoplasiasResumen
Bioengineering is an area of biotechnology that offers tools for different therapeutic strategies, including tissue therapies. For this, cells are associated with growth factors and scaffolds composed of biocompatible biomaterials capable of promoting the regeneration of tissues, such as bones. Autologous biomaterials produced from human peripheral blood have a proven ability to produce/release activating factors for tissue repair, with potential application as a vehicle for carrying substances for local release. The present idea proposes the use of a new blood-derived concentrate, Alb-PRF, an activated plasma albumin gel with the platelet-rich fibrin in the liquid phase (Liquid PRF). Alb-PRF can be able to stabilize the fibrin matrix of the scaffold, acting as a drug delivery system vehicle in malignant lesions.
Descargas
Citas
Tangen O, Berman HJ, Marfey P. Gel filtration. A new technique for separation of blood platelets from plasma. Thromb Diath Haemorrh. 1971;25(2):268-78. DOI: https://doi.org/10.1055/s-0038-1654301
Ross R, Glomset J, Kariya B, et al. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci U S A. 1974;71(4):1207-10. doi: https://doi.org/10.1073/pnas.71.4.1207 DOI: https://doi.org/10.1073/pnas.71.4.1207
Mourão CFAB, Gheno E, Lourenço ES, et al. Characterization of a new membrane from concentrated growth factors associated with denaturized Albumin (Alb-CGF) for clinical applications: a preliminary study. Int J Growth Factors Stem Cells Dent. 2018;1(2):64-9. doi: https://doi.org/10.4103/GFSC.GFSC_21_18 DOI: https://doi.org/10.4103/GFSC.GFSC_21_18
Lourenço ES, Mourão CFAB, Leite PEC, et al. The in vitro release of cytokines and growth factors from fibrin membranes produced through horizontal centrifugation. J Biomed Mater Res A. 2018;106(5):1373-80. doi: https://doi.org/10.1002/jbm.a.36346 DOI: https://doi.org/10.1002/jbm.a.36346
Gheno E, Mourão CFAB, Mello-Machado RC, et al. In vivo evaluation of the biocompatibility and biodegradation of a new denatured plasma membrane combined with liquid PRF (Alb-PRF). Platelets. 2021;32(4):542-54. doi: https://doi.org/10.1080/09537104.2020.1775188 DOI: https://doi.org/10.1080/09537104.2020.1775188
Miron RJ, Xu H, Chai J, et al. Comparison of platelet-rich fibrin (PRF) produced using 3 commercially available centrifuges at both high (~ 700 g) and low (~ 200 g) relative centrifugation forces. Clin oral investig. 2020;24(3):1171-82. doi: https://doi.org/10.1007/s00784-019-02981-2 DOI: https://doi.org/10.1007/s00784-019-02981-2
Mourão CFAB, Mello-Machado RC, Javid K, et al. The use of leukocyte- and platelet-rich fibrin in the management of soft tissue healing and pain in post-extraction sockets: a randomized clinical trial. J Craniomaxillofac Surg. 2020;48(4):452-7. doi: https://doi.org/10.1016/j.jcms.2020.02.020 DOI: https://doi.org/10.1016/j.jcms.2020.02.020
Moraschini V, Mourão CFAB, Machado RCM, et al. Does platelet-rich fibrin decrease dimensional changes and improve postoperative comfort in post-extraction sockets? An overview of systematic reviews. Appl Sci (Basel). 2020;10(17):5750. doi: https://doi.org/10.3390/app10175750 DOI: https://doi.org/10.3390/app10175750
Ma Y, Cai F, Li Y, et al. A review of the application of nanoparticles in the diagnosis and treatment of chronic kidney disease. Bioact Mater. 2020;5(3):732-43. doi: https://doi.org/10.1016/j.bioactmat.2020.05.002 DOI: https://doi.org/10.1016/j.bioactmat.2020.05.002
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Os direitos morais e intelectuais dos artigos pertencem aos respectivos autores, que concedem à RBC o direito de publicação.
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
